A detailed history of Prelude Capital Management, LLC transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Prelude Capital Management, LLC holds 21,935 shares of PCRX stock, worth $364,121. This represents 0.02% of its overall portfolio holdings.

Number of Shares
21,935
Previous 21,935 -0.0%
Holding current value
$364,121
Previous $330,000 -0.0%
% of portfolio
0.02%
Previous 0.01%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$11.7 - $28.46 $29,460 - $71,662
2,518 Added 12.97%
21,935 $330,000
Q2 2024

Aug 14, 2024

BUY
$25.5 - $31.51 $124,746 - $154,146
4,892 Added 33.68%
19,417 $555,000
Q1 2024

May 15, 2024

BUY
$27.7 - $35.48 $217,195 - $278,198
7,841 Added 117.31%
14,525 $424,000
Q4 2023

Feb 14, 2024

BUY
$26.32 - $34.31 $175,922 - $229,328
6,684 New
6,684 $225,000
Q2 2023

Aug 14, 2023

BUY
$36.12 - $47.5 $252,478 - $332,025
6,990 New
6,990 $280,000
Q2 2022

Aug 15, 2022

BUY
$51.49 - $81.64 $128,261 - $203,365
2,491 Added 33.91%
9,837 $573,000
Q1 2022

May 16, 2022

SELL
$60.03 - $76.49 $268,994 - $342,751
-4,481 Reduced 37.89%
7,346 $561,000
Q4 2021

Feb 14, 2022

BUY
$47.97 - $62.21 $567,341 - $735,757
11,827 New
11,827 $712,000
Q3 2020

Nov 16, 2020

SELL
$51.97 - $63.0 $802,780 - $973,161
-15,447 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$30.8 - $52.47 $94,186 - $160,453
3,058 Added 24.68%
15,447 $811,000
Q1 2020

May 15, 2020

BUY
$28.4 - $50.7 $195,250 - $348,562
6,875 Added 124.68%
12,389 $415,000
Q4 2019

Feb 14, 2020

SELL
$36.31 - $46.83 $114,739 - $147,982
-3,160 Reduced 36.43%
5,514 $250,000
Q3 2019

Nov 14, 2019

SELL
$35.66 - $44.99 $308,565 - $389,298
-8,653 Reduced 49.94%
8,674 $330,000
Q2 2019

Aug 14, 2019

BUY
$36.57 - $47.97 $626,114 - $821,294
17,121 Added 8311.17%
17,327 $754,000
Q1 2019

May 15, 2019

BUY
$36.47 - $42.17 $7,512 - $8,687
206 New
206 $8,000

Others Institutions Holding PCRX

About Pacira BioSciences, Inc.


  • Ticker PCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 45,824,200
  • Market Cap $761M
  • Description
  • Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...
More about PCRX
Track This Portfolio

Track Prelude Capital Management, LLC Portfolio

Follow Prelude Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Prelude Capital Management, LLC with notifications on news.